Janssen AD26 vaccine (JNJ-78436735) living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

6484	Sadoff, 2021	1	1			risk of bias not avaialble
6904	HORIZON 1, 0	0	31	selection pending
6949	Pawlowski, 2021	1	13		not a RCT	risk of bias not avaialble
8162	Johnson and Johnson, 2021	0	0	selection pending
8295	Sisonke (JNJ South Africa heathworkers), 0	0	13	selection pending
9173	Sisonke 2 (booster), 2021	1	20		not a RCT	risk of bias not avaialble
9274	MixNMatch Study, 2021	1	10		not a RCT	risk of bias not avaialble
9312	Reindl-Schwaighofer, 2021	1	1			risk of bias not avaialble
9343	EPIPHARE (Janssen), 2022	1	12		not a RCT	risk of bias not avaialble
9361	Husby (janssen), 2021	1	12		not a RCT	risk of bias not avaialble
9404	Botton (EPI-PHARE), 2022	1	12		not a RCT	risk of bias not avaialble
9580	Sisonke study (bekker), 2022	0	0	selection pending

	COVID-19 prophylaxis (excluding children)
Janssen AD26 vaccine (JNJ-78436735)	ENSEMBLE ...